Market Overview

Valeant Ditches Philidor: Here's What It Really Means

Share:
Valeant Ditches Philidor: Here's What It Really Means
  • Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has announced it is cutting ties with Philidor RX Services.
  • Valeant’s stock is down 6 percent on the news.
  • Analysts are downplaying the impact that the decision will ultimately have on Valeant.

Valeant shares are down 6 percent in early trading on Friday following an announcement that it will sever ties with controversial mail-order pharmacy Philidor RX Services, LLC. Separately on Friday, Bill Ackman gave a conference call about Valeant.

Here’s a look at what four Wall Street firms have to say about the impact the move will have on Valeant shareholders.

Bank of America

Analyst Sumant Kulkami believes the financial impact of the decision will be minimal for Valeant and predicts that “VRX’s diverse business mix, durable asset base, and low product concentration risk position VRX to generate solid cash flow and de-lever to its goal of below 4x adj. EBITDA by the end of 2016."

The firm maintains its Buy rating and $173 price objective.

Related Link: Bank Of America Is Buying Valeant's Philidor Selloff

JP Morgan

Analyst Chris Schott believes that the decision for Valeant to drop Philidor will be "ultimately well-received by the market.” He notes that Philidor represents about 7 percent of Valeant’s revenue, but expects that Valeant will quickly fill some of Philidor’s void by adding another independent specialty pharmacy.

JP Morgan maintains its Overweight rating on Valeant.

Stifel

Analyst Annabel Samimy bluntly explains that Valeant’s “Philidor relationship is just not that important,” adding that Valeant has only “modest” revenue exposure to the controversial pharmacy. Stifel maintains its Buy rating and $285 target for Valeant.

Morgan Stanley

Analyst David Risinger believes that the largest impact on Valeant will not be on revenue, but rather on growth. “Philidor and related specialty pharmacies accounted for only 7.2% of global revenue; we estimate Philidor contributed over a third of reported 27% US organic growth,” he explained.

Morgan Stanley maintains an Equal-Weight rating on Valeant.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018DowngradesBuyHold
Jun 2018UpgradesEqual-WeightOverweight
May 2018UpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Bank of America JP MorganAnalyst Color Biotech Health Care Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
KHCUBSMaintains31.0
RPAYCantor FitzgeraldMaintains18.0
CMSCredit SuisseDowngrades
PBCTStephens & Co.Maintains15.5
TTECCowen & Co.Initiates Coverage On50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com